IP Library Granted Patent US 8,129,121
Granted Patent B2
US 8,129,121 · App. 12/448,840 · Granted Mar 6, 2012

Regulation of lipid droplet formation by modulation of FIT1 and FIT2 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,129,121
App. No.
12/448,840
Granted
Mar 6, 2012
Kind
B2
Abstract

This invention provides methods of regulating fat storage in tissue by modulating the levels of Fibrate Induced Transcript 1 (FIT1) and/or Fibrate Induced Transcript 2 (FIT2), as well as diagnostic screens for disorders and conditions involving regulation of fat storage in tissue, assays for identifying agents that can regulate fat storage in tissue through modulating the levels of FIT1 and/or FIT2, and genetically altered mammals in which expression of FIT1 and/or FIT2 is altered in one or more tissue.

Claims (14)

1. A method for screening for a candidate agent that can reduce fat storage in tissue by determining whether or not the agent is effective to decrease the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with cells or tissue that express FIT1 and/or FIT2, and wherein reduction in expression or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for decreasing fat storage in tissue.

2. A method for screening for a candidate agent that can increase fat storage in tissue by determining whether or not the agent is effective to increase the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with cells or tissue that express FIT1 and/or FIT2, and wherein an increase in expression or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for increasing fat storage in tissue.

3. The method of claim 2 , wherein the cells are mouse embryo fibroblasts isolated from FIT2 knockout embryos, and wherein the fibroblasts are stably or transiently transfected with FIT1 and/or FIT2 under control of a regulated or constitutively active promoter.

4. The method of claim 2 , wherein the agent affects expression of FIT1 and/or FIT2.

5. The method of claim 2 , wherein the agent affects activity of FIT1 and/or FIT2.

6. The method of claim 2 , wherein the agent affects FIT1.

7. The method of claim 2 , wherein the agent affects FIT2.

8. The method of claim 2 , wherein the agent affects FIT1 and FIT2.

9. The method of claim 1 , wherein the cells are mouse embryo fibroblasts isolated from FIT2 knockout embryos, and wherein the fibroblasts are stably or transiently transfected with FIT1 and/or FIT2 under control of a regulated or constitutively active promoter.

10. The method of claim 1 , wherein the agent affects expression of FIT1 and/or FIT2.

11. The method of claim 1 , wherein the agent affects activity of FIT1 and/or FIT2.

12. The method of claim 1 , wherein the agent affects FIT1.

13. The method of claim 1 , wherein the agent affects FIT2.

14. The method of claim 1 , wherein the agent affects FIT1 and FIT2.

Assignments (2)
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036873/0672 →